Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06419413 | RECRUITING | Asthma

A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
Sponsor:

AstraZeneca

Brief Summary:

A Translational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes associated with Differential Outcomes that may Support Future Development of Personalised Treatment Strategies in Chinese Population

Condition or disease

Asthma

Study Type : OBSERVATIONAL
Estimated Enrollment : 355 participants
Official Title : A Transnational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes That May Support Future Development of Personalized Treatment Strategies in Chinese Population
Actual Study Start Date : 2024-01-08
Estimated Primary Completion Date : 2026-10-08
Estimated Study Completion Date : 2026-10-08

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years to 75 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: 1
Criteria
Inclusion Criteria
  • * Age 18 to 75 years of age
  • * acceptable FEV1 (according to ATS and ERS)
  • * compliance with study procedures All Asthma Cohorts
  • * physician diagnosed Asthma greater or equal to 3 months prior to screening visit
Exclusion Criteria
  • * history of alcohol or drug abuse within the past year
  • * pregnant at time of an assessment
  • * has an altered mental status at the time of informed consent
  • * receipt marketed or investigational biologic(s) within 3 months or 5 half-lives prior to visit 1, whichever is longer
  • * history or current upper or lower respiratory infection or symptoms within 2 weeks of baseline assessments
  • * terminal diseases and/or organ failure or participants otherwise considered not appropriate for the study participation
  • * Receipt LTRAs or 5-lipoxygenase (5-LO) inhibitors (eg zileuton and montelukast) within 1 month or 5 half-lives prior to baseline, whichever is longer.
A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population

Location Details

NCT06419413

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

China, Sichuan

Research Site

Chengdu, Sichuan, China,

NOT YET RECRUITING

China,

Research Site

Beijing, China,

NOT YET RECRUITING

China,

Research Site

Changsha, China,

NOT YET RECRUITING

China,

Research Site

Dongguan, China,

NOT YET RECRUITING

China,

Research Site

Foshan, China,

NOT YET RECRUITING

China,

Research Site

Guangzhou, China,

NOT YET RECRUITING

China,

Research Site

Hainan, China,

NOT YET RECRUITING

China,

Research Site

Hohhot, China,

NOT YET RECRUITING

China,

Research Site

Huizhou, China,

NOT YET RECRUITING

China,

Research Site

Kunming, China,

NOT YET RECRUITING

China,

Research Site

Nanjing, China,

NOT YET RECRUITING

China,

Research Site

Nanning, China,

NOT YET RECRUITING

China,

Research Site

Shanghai, China,

NOT YET RECRUITING

China,

Research Site

Shenyang, China,

RECRUITING

China,

Research Site

Taiyuan, China,

NOT YET RECRUITING

China,

Research Site

Wenzhou, China,

RECRUITING

China,

Research Site

Wuhan, China,

RECRUITING

China,

Research Site

Xi'an, China,

NOT YET RECRUITING

China,

Research Site

Xuzhou, China,

NOT YET RECRUITING

China,

Research Site

Zhanjiang, China,

NOT YET RECRUITING

China,

Research Site

Zhaoqing, China,